Keay Nakae
Stock Analyst at Chardan Capital
(2.84)
# 1,576
Out of 4,814 analysts
215
Total ratings
26.32%
Success rate
1.19%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Initiates: Buy | $25 | $13.46 | +85.74% | 1 | Apr 16, 2025 | |
| SONN Sonnet BioTherapeutics Holdings | Maintains: Buy | $20 | $1.26 | +1,487.30% | 14 | Apr 7, 2025 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $25 → $20 | $1.39 | +1,338.85% | 14 | Apr 1, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $2.86 | +599.30% | 8 | Apr 1, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $6 | $1.74 | +244.83% | 7 | Mar 28, 2025 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 | $3.06 | +63.40% | 12 | Mar 28, 2025 | |
| ALUR Allurion Technologies | Maintains: Neutral | $2.5 | $2.25 | +11.11% | 6 | Mar 27, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 | $230.50 | +30.15% | 12 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $1.25 | $0.40 | +212.58% | 9 | Mar 20, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $5.22 | +168.20% | 16 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 | $7.83 | +538.57% | 10 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 | $25.74 | +152.53% | 14 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.14 | +250.88% | 14 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 | $11.35 | +428.63% | 18 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 | $2.90 | +1,796.55% | 10 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $1.08 | +640.74% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $0.98 | +410.26% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.08 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $10.31 | -41.80% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $20 | $0.53 | +3,708.80% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $4.62 | +1,090.48% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $11.41 | -12.36% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $7.00 | +1,150.89% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $0.65 | +1,890.20% | 3 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $155 → $40 | $2.84 | +1,308.45% | 2 | Jun 30, 2020 |
Korro Bio
Apr 16, 2025
Initiates: Buy
Price Target: $25
Current: $13.46
Upside: +85.74%
Sonnet BioTherapeutics Holdings
Apr 7, 2025
Maintains: Buy
Price Target: $20
Current: $1.26
Upside: +1,487.30%
SAB Biotherapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $1.39
Upside: +1,338.85%
Orchestra BioMed Holdings
Apr 1, 2025
Maintains: Buy
Price Target: $20
Current: $2.86
Upside: +599.30%
Gain Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $1.74
Upside: +244.83%
Arbutus Biopharma
Mar 28, 2025
Maintains: Buy
Price Target: $5
Current: $3.06
Upside: +63.40%
Allurion Technologies
Mar 27, 2025
Maintains: Neutral
Price Target: $2.5
Current: $2.25
Upside: +11.11%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $300
Current: $230.50
Upside: +30.15%
Seres Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $1.25
Current: $0.40
Upside: +212.58%
Coya Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $14
Current: $5.22
Upside: +168.20%
Mar 17, 2025
Maintains: Buy
Price Target: $50
Current: $7.83
Upside: +538.57%
Mar 17, 2025
Maintains: Buy
Price Target: $65
Current: $25.74
Upside: +152.53%
Mar 14, 2025
Maintains: Buy
Price Target: $4
Current: $1.14
Upside: +250.88%
Feb 11, 2025
Maintains: Buy
Price Target: $60
Current: $11.35
Upside: +428.63%
Dec 10, 2024
Maintains: Buy
Price Target: $55
Current: $2.90
Upside: +1,796.55%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.08
Upside: +640.74%
Jun 3, 2024
Maintains: Buy
Price Target: $5
Current: $0.98
Upside: +410.26%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $10.31
Upside: -41.80%
Nov 10, 2022
Maintains: Buy
Price Target: $60 → $20
Current: $0.53
Upside: +3,708.80%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $4.62
Upside: +1,090.48%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $11.41
Upside: -12.36%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $7.00
Upside: +1,150.89%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $0.65
Upside: +1,890.20%
Jun 30, 2020
Downgrades: Neutral
Price Target: $155 → $40
Current: $2.84
Upside: +1,308.45%